Effect of Danhong injection on pharmacokinetics and pharmacodynamics of rivaroxaban in rats

被引：1
作者：
Yin, Weihong [1 ]
Li, Jiao [1 ]
Han, Zhaoyang [1 ]
Wang, Siwen [1 ]
Wu, Fan [1 ]
Yu, Chao [1 ]
Yan, Xueying [1 ]
Cui, Mingyu [1 ]
机构：
[1] Heilongjiang Univ Chinese Med, Coll Pharm, Harbin 150040, Peoples R China
来源：
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY | 2025年 / 398卷 / 04期
基金：
美国国家科学基金会;
关键词：
Rivaroxaban; Danhong injection; Pharmacokinetics; Pharmacodynamics; Herb-drug interactions; DIRECT ORAL ANTICOAGULANTS; NF-KAPPA-B; SALVIANOLIC ACID; RISK; INHIBITION; INFLAMMATION; ASSOCIATION; MEDICATIONS; THROMBOSIS; PROMOTION;
D O I：
10.1007/s00210-024-03453-5
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Background and objectives Rivaroxaban is often used in combination with DHI to treat thromboembolic disease. Whether the combination causing HDIs is still unknown. The purpose of this study was to evaluate effects of DHI on pharmacokinetics and pharmacodynamics of rivaroxaban in rats and effects on CYP3A2. Methods Plasma concentration of rivaroxaban with or without DHI was determined by HPLC. Pharmacokinetics parameters were calculated. Effect of DHI on pharmacodynamics of rivaroxaban was investigated by APTT, PT, TT, FIB, INR, length of tail thrombosis, vWF, t-PA, PAI-1, IL-1 beta, TNF-alpha and histopathological sections. Effect of DHI on CYP3A2 in rats was investigated by probe drug method. Results C-max and AUC of rivaroxaban increased significantly in combination group (P < 0.05). APTT, PT, INR and TT increased (P < 0.05), length of tail thrombosis, FIB, vWF, PAI-1, IL-1 beta and TNF-alpha of combination group decreased significantly (P < 0.05) compared with rivaroxaban or DHI alone. Histopathologic section of tail thrombus had significant improvement. C-max and AUC of dapsone increased (P < 0.05) in DHI group. Conclusion In summary, DHI is an inhibitor of CYP3A2 and could significantly affect pharmacokinetics and pharmacodynamic of rivaroxaban, enhance anticoagulant and antithrombotic efficacy in rats. However, the combination of rivaroxaban and DHI might lead to potential HDIs. The dosage of rivaroxaban should be adjusted in clinical.
引用
收藏
页码：3617 / 3629
页数：13
相关论文
共 89 条
[1]   Risk factors for venous thromboembolism [J].
Anderson, FA ;
Spencer, FA .
CIRCULATION, 2003, 107 :I9-I16
[2]   Endothelial Dysfunction and Inflammatory Markers of Vascular Disease [J].
Balta, Sevket .
CURRENT VASCULAR PHARMACOLOGY, 2021, 19 (03) :243-249
[3]  
Branchford B.R., 2018, Frontiers in pediatrics, V6, P142, DOI [DOI 10.3389/FPED.2018.00142, 10.3389/fped.2018.00142]
[4]   Perpetrator effects of ciclosporin (P-glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers [J].
Brings, Antonia ;
Lehmann, Marie-Louise ;
Foerster, Kathrin, I ;
Burhenne, Juergen ;
Weiss, Johanna ;
Haefeli, Walter E. ;
Czock, David .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (07) :1528-1537
[5]   Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism [J].
Buller, Harry R. ;
Prins, Martin H. ;
Lensing, Anthonie W. A. ;
Decousus, Herve ;
Jacobson, Barry F. ;
Minar, Erich ;
Chlumsky, Jaromir ;
Verhamme, Peter ;
Wells, Phil ;
Agnelli, Giancarlo ;
Cohen, Alexander ;
Berkowitz, Scott D. ;
Bounameaux, Henri ;
Davidson, Bruce L. ;
Misselwitz, Frank ;
Gallus, Alex S. ;
Raskob, Gary E. ;
Schellong, Sebastian ;
Segers, Annelise .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (14) :1287-1297
[6]  
Chai HQ., 2019, PRACT J CARD CEREB P, V27, P70
[7]   Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation [J].
Chang, Shang-Hung ;
Chou, I-Jun ;
Yeh, Yung-Hsin ;
Chiou, Meng-Jiun ;
Wen, Ming-Shien ;
Kuo, Chi-Tai ;
See, Lai-Chu ;
Kuo, Chang-Fu .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (13) :1250-1259
[8]   Danhong Injection Enhances the Therapeutic Efficacy of Mesenchymal Stem Cells in Myocardial Infarction by Promoting Angiogenesis [J].
Chen, Jingrui ;
Wei, Jing ;
Huang, Yuting ;
Ma, Yuling ;
Ni, Jingyu ;
Li, Min ;
Zhu, Yan ;
Gao, Xiumei ;
Fan, Guanwei .
FRONTIERS IN PHYSIOLOGY, 2018, 9
[9]   Use of Diterpene Ginkgolides Meglumine Injection to Regulate Plasma Levels of PAI-1 and t-PA in Patients With Acute Atherosclerotic Cerebral Infarction [J].
Chen, Rui ;
Yan, Luxia ;
Xie, Peng ;
Tian, Jisha ;
Zhao, Ying ;
Liu, Yue ;
Xu, Jie ;
Wang, Yuqian ;
Zhao, Liandong .
NEUROLOGIST, 2022, 27 (06) :299-303
[10]   Real-world clinical outcomes of oral anticoagulants among Japanese patients with atrial fibrillation and concomitant coronary artery disease [J].
Chen, Yijiao ;
Gong, Xiaoqian ;
Bao, Haikun .
IJC HEART & VASCULATURE, 2023, 49
123456789